A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Status:
Completed
Trial end date:
2016-08-10
Target enrollment:
Participant gender:
Summary
Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter
study to evaluate the safety and efficacy of two dose levels of pregabalin administered in
equally divided daily doses, in either capsule or oral liquid formulation, as adjunctive
therapy in pediatric subjects 4 to 16 years of age with partial onset seizures.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.